Welcome to our dedicated page for Vitrolife news (Ticker: VTRLY), a resource for investors and traders seeking the latest updates and insights on Vitrolife stock.
The VTRLY news page tracks company communications and market-facing updates related to Vitrolife AB (publ), a biotechnology group active in reproductive health. Investors can use this feed to follow how the Vitrolife Group reports on its regional and product group performance, as well as strategic and financing developments that may influence the underlying business.
Vitrolife AB (publ) regularly publishes interim reports that detail sales in local currencies across EMEA, Americas and APAC, and across its Consumables, Technologies and Genetics product groups. These reports discuss organic growth excluding discontinued business, currency effects on sales and margins, gross margin levels, EBITDA, operating cash flow and net income. News items linked to these reports often include conference call invitations, where management presents the results and answers questions from investors, analysts and financial media.
The news flow also covers strategic initiatives and organisational changes. For example, Vitrolife AB (publ) has announced that it became a leading investor in AutoIVF, an early-stage MedTech company focused on making IVF more accessible, affordable and efficient through its OvaReady™ technology. The company has also communicated changes to its Executive Management Team, including the introduction of a SVP Innovation role to oversee R&D, Strategy & Sustainability, Portfolio Lifecycle Management and Market Access.
Governance and capital structure events appear in the form of Annual General Meeting notices and reports, which describe proposed and approved dividends, Board elections, auditor re-elections, share issue and share repurchase authorisations and share-based incentive programs. Financing news includes announcements such as the renewal and signing of a loan agreement comprising a term loan and revolving credit facility backed by Nordic banks.
By reviewing the VTRLY news feed, readers can follow how Vitrolife AB (publ) communicates on financial performance, IVF-related strategic investments, executive appointments, governance decisions and loan facilities. This makes the page a useful reference for anyone monitoring the company’s publicly disclosed developments over time.
Vitrolife invites stakeholders to a conference call on April 22, 2022, at 10:00 a.m. CET for the presentation of its interim report for January-March 2022. Dial-in details are provided for Sweden and internationally, with a conference ID of 6938009. The interim report will be released at 8:00 a.m. CET on the same day, and presentation materials will be accessible on the company’s website. A recorded version of the call will be available for seven days post-event. Contact for inquiries is Patrik Tolf, CFO.
On March 30, 2022, Vitrolife published its Annual Report for 2021, detailing the company's financial performance and strategic initiatives. The report is accessible via their website and printed copies will be mailed to shareholders who have requested them starting the week of April 11. Patrik Tolf, the CFO, can be contacted for further inquiries. This announcement seeks to inform stakeholders about the company's financial status and maintain transparency with shareholders.
The Annual General Meeting of Vitrolife AB is scheduled for April 27, 2022, at 4:00 PM in Gothenburg, Sweden. Shareholders must register by April 19, 2022, and confirm attendance by April 21, 2022. Key proposals include a dividend of SEK 0.80 per share and the election of six Board members, including re-election of Jón Sigurdsson as Chairman. The proposed Board fee totals SEK 3,600,000, revealing an increase from the previous year. The meeting will also address amendments to the Articles of Association and authorize share issues and acquisitions.
The Board of Directors of Vitrolife AB has announced the date for its Annual General Meeting, to be held on April 27, 2022, at 4:00 PM in Gothenburg, Sweden. A formal notice will be published by March 30, 2022. This meeting provides shareholders with the opportunity to participate in decisions regarding company operations and governance.
Vitrolife AB reported strong Q4 2021 results with sales reaching SEK 514 million, a 35% year-over-year increase. Genetic Services, boosted by the Igenomix acquisition, contributed SEK 116 million in December alone. The full year sales totaled SEK 1,681 million, marking a 35% growth, with a net income of SEK 344 million. An adjusted EBITDA margin of 38% reflects solid operational performance, despite currency impacts. The Board proposed maintaining a dividend of SEK 0.80 per share.
Vitrolife invites investors to a conference call on February 16, 2022, at 10:00 a.m. CET to discuss the Report on Operations 2021. The call will feature CEO Thomas Axelsson and CFO Patrik Tolf. Participants can register 10-15 minutes prior, using the provided international dial-in numbers. The report will be released at 8:00 a.m. CET on the same day, with presentation materials available on the company's website. A recorded version of the call will be accessible for seven days after the event.
On December 30, 2021, Vitrolife AB announced the issuance of 17,251,312 new shares following a decision made at the Extraordinary General Meeting on October 20, 2021. This increase brings the total number of shares to 135,447,190 as of the announcement date. This change is part of the company's compliance with the Swedish Financial Instruments Trading Act and aims to enhance liquidity and shareholder value.
On December 7, 2021, Vitrolife's CEO Thomas Axelsson sold 38,300 shares for approximately SEK 18.7 million. This sale leaves him with 13,000 shares remaining. Axelsson cited the positive development of the share price since his acquisition in 2012 as a reason to realize part of his profit for personal financial needs. The transaction will be reported to the Swedish Financial Supervisory Authority per regulations. This announcement is mandated under the EU Market Abuse Regulation, with details provided at 10:50 am CET.
Vitrolife AB has completed the acquisition of 100% of Igenomix S.L., following regulatory approvals. The deal includes a non-cash consideration issue that increases the total number of shares from 118,195,878 to 135,447,190, resulting in a dilution of approximately 13%. For the period from January 1 to September 30, 2021, Igenomix generated revenues of EUR 91.4 million, with an adjusted EBITDA of EUR 23.3 million. The integration of Igenomix will be effective from December 1, 2021, postponing the 2021 report on operations to February 16, 2022.
Vitrolife AB has announced a prospectus for the trading of newly issued shares on Nasdaq Stockholm. This follows a non-cash issue to acquire all shares in Mendel Holdco S.L., and indirectly in Igenomix S.L.. The total number of shares will rise by 17,251,312, increasing the share capital to SEK 27,631,226.760. Existing shareholders will experience a 12.7% dilution of their capital and votes. The prospectus is now available from the Swedish Financial Supervisory Authority and the company’s website.